RNATICS receives prestigious Pharma Innovation Top 2 Award 2022 for novel RNA therapeutic against COVID-19More Details
To exploit our unique delivery technology targeted to tissue macrophages for the development of a new class of RNA therapeutics.
RNATICS develops RNA therapeutics directed at disease-causing RNAs in tissue resident macrophages. These immune cells are increasingly recognized as a key cell population in a rapidly increasing number of hard-to-treat severe diseases. Our proprietary targeting technology via carbohydrate-coupling allows efficient delivery of our RNA therapeutics to tissue macrophages and modulate their disease-causing activity. This novel delivery pathway enables access to organs previously not accessible to RNA therapeutics offering tremendous therapeutic opportunities for multiple diseases.
Most advanced towards clinical application is our lung program that targets pulmonary macrophages to treat pulmonary hyperinflammation and fibrosis in COVID-19. IND-enabling work is ongoing, and we aim to begin first-in-human studies by the end of this year.